Open Nav

AcuraStem Incorporated

  • Sam Alworth, AcuraStem Incorporated

Meet Investors

  • Date:Wednesday, October 17
  • Time:10:15 AM - 10:30 AM
  • Room:Elizabethan A
  • Location:2nd Floor
  • Session Type:Company Presentation
  • Presentation Type:Privately Funded Company
  • Company Description/Mission Statement:AcuraStem utilizes advanced stem cell technology and artificial intelligence to predict drug efficacy for neurodegenerative disease using living neurons from current patients – a virtual nerve biopsy. AcuraStem has used this technology platform, iNeuroRX™, to discover and bring forward a novel and potentially curative preclinical ALS therapeutic candidate, winning over $4M in grant funding from the NIH and the Muscular Dystrophy Association for this effort; iNeuroRx™ was born out of research from the lab of AcuraStem’s President and co-founder Dr. Justin Ichida, and heralded in the February 5, 2018 issue of Nature Medicine.
  • Company
  • Company HQ City:Los Angeles
  • Company HQ Country:United States
  • Company HQ State:California                  
  • CEO/Top Company Official:Sam Alworth
  • Year Founded:2016
  • Main Therapeutic Focus:CNS/Neurological
  • Lead Product in Development :AS 2015
  • Development Phase of Primary Product:Pre-Clinical
  • Number Of Unlicensed Products (For Which You Are Seeking Partners) :1
  • Additional Information/Comments:Neurodegenerative disease models have not been predictive. AcuraStem is leading a new generation of Patient-based drug discovery that uses"virtual nerve biopsies" from patients. These personalized disease models have the exact same genetic background as patients and exhibit endogenous disease signatures without genetic manipulation. This is a game-changing approach to tackling neurodegenerative diseases. Using the iNeuroRx platform we have discovered a compelling and novel preclinical candidate for ALS, best-in-class because it has potential to cure the disease rather than simply addressing symptoms. The discovery was uniquely enabled by the patient platform because the therapeutic's mechanism of action addresses both a gain and loss of function that would have difficult to mimic with engineered models. We are actively using this proprietary platform to advance additional novel targets in ALS and other neurodegenerative diseases.
  • Size of Last Investment Round:Pre-venture
  • Total Amount Raised to Date, In All Rounds:$4.1M Grants, Founders, Friends and Family
Sam Alworth
AcuraStem Incorporated